España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Marinus Pharma
MRNS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.301400
-0.0076
-2.46%
Pre-Market: 6:21 AM EDT
Get Report
Comment
Marinus Pharma (MRNS) Forecast
News
Earnings
Marinus Pharma (MRNS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Marinus Pharma (NASDAQ:MRNS) Stock
Marinus Pharma Stock (NASDAQ: MRNS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 14, 2024
Cantor Fitzgerald Reiterates Overweight on Ma...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Neutral on Mar...
Benzinga Newsdesk
Wednesday, November 13, 2024
D. Boral Capital Maintains Buy on Marinus Pha...
Benzinga Newsdesk
Tuesday, November 12, 2024
Marinus Pharma Q3 EPS $(0.42) Misses $(0.41) ...
Benzinga Newsdesk
Tuesday, October 29, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
Monday, October 28, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Friday, October 25, 2024
HC Wainwright & Co. Downgrades Marinus Pharma...
Benzinga Newsdesk
TD Cowen Downgrades Marinus Pharma to Hold
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on Marin...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Overweight on Mar...
Benzinga Newsdesk
Jefferies Downgrades Marinus Pharma to Hold, ...
Benzinga Newsdesk
Thursday, October 24, 2024
Crude Oil Down 1%; Dow Posts Upbeat Earnings
Avi Kapoor
JMP Securities Downgrades Marinus Pharma to M...
Benzinga Newsdesk
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Vandana Singh
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
Avi Kapoor
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
Avi Kapoor
EF Hutton Maintains Buy on Marinus Pharma, Lo...
Benzinga Newsdesk
Marinus Pharmaceuticals shares are trading lo...
Benzinga Newsdesk
Trading Halt: Halt status updated at 8:25:00 ...
Benzinga Newsdesk
Marinus Pharmaceuticals Reports Phase 3 Trust...
Benzinga Newsdesk
Marinus Pharmaceuticals Shares Halted Pending...
Benzinga Newsdesk
Trading Halt: Halted at 7:55:00 a.m. ET - Tra...
Benzinga Newsdesk
Thursday, October 17, 2024
EF Hutton Maintains Buy on Marinus Pharma, Ma...
Benzinga Newsdesk
Marinus Pharmaceuticals Presented New Data Fr...
Benzinga Newsdesk
Marinus Pharmaceuticals Presented Data From P...
Benzinga Newsdesk
Wednesday, October 16, 2024
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
MarketBeat
Tuesday, October 15, 2024
Marinus Pharmaceuticals Further Strengthens I...
Benzinga Newsdesk
Friday, October 11, 2024
EF Hutton Maintains Buy on Marinus Pharma, Ma...
Benzinga Newsdesk
Wednesday, October 09, 2024
Marinus Pharmaceuticals Announced That Additi...
Benzinga Newsdesk
Monday, October 07, 2024
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
MarketBeat
Monday, September 30, 2024
EF Hutton Initiates Coverage On Marinus Pharm...
Benzinga Newsdesk
Tuesday, September 24, 2024
Cantor Fitzgerald Reiterates Overweight on Ma...
Benzinga Newsdesk
Monday, September 23, 2024
Oppenheimer Upgrades Marinus Pharma to Outper...
Benzinga Newsdesk
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on Ma...
Benzinga Newsdesk
Monday, September 09, 2024
Cantor Fitzgerald Reiterates Overweight on Ma...
Benzinga Newsdesk
Wednesday, August 14, 2024
HC Wainwright & Co. Reiterates Buy on Marinus...
Benzinga Newsdesk
Ladenburg Thalmann Downgrades Marinus Pharma ...
Benzinga Newsdesk
Tuesday, August 13, 2024
Marinus Pharmaceuticals Says It Is On Track T...
Benzinga Newsdesk
Marinus Pharma Q2 EPS $(0.63) Misses $(0.59) ...
Benzinga Newsdesk
Thursday, July 18, 2024
China National Medical Products Administratio...
Benzinga Newsdesk
Tuesday, June 18, 2024
Truist Securities Maintains Buy on Marinus Ph...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Marinus...
Benzinga Newsdesk
Monday, June 17, 2024
Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients
Vandana Singh
Marinus Pharmaceuticals Announced Topline Res...
Benzinga Newsdesk
Thursday, June 13, 2024
Avidity Up 33% on Rare Muscle Disease Study Results
Zacks
Ultragenyx Posts New Data From Bone Disease Study
Zacks
Friday, May 24, 2024
Candel Reports Upbeat Data From Lung Cancer Study
Zacks
Friday, May 17, 2024
Marinus Pharmaceuticals Wraps Phase 3 Trial E...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch